)
Edge12 Dec 2025
Running on Clouds: The Story of On
The story of how a Swiss runner's pursuit of a new running sensation became On, aiming to be the most premium global sportswear brand worldwide.
Denali Therapeutics
Denali Therapeutics (DNLI) investor relations material
Denali Therapeutics 44th Annual J.P. Morgan Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.44th Annual J.P. Morgan Healthcare Conference summary13 Jan, 2026
Strategic vision and technology platform
Focused on delivering biotherapeutics to the brain and body using the TransportVehicle platform, leveraging transferrin receptor-mediated delivery for broad tissue access and systemic delivery of enzymes, oligonucleotides, and antibodies.
Transitioned from a science-driven to a development and commercial organization, with in-house manufacturing, 520+ employees, and a strong financial position to support growth.
Platform validated with over 200 subjects dosed, 11,000+ doses administered, and 20+ publications in five years.
Prioritizes indications with well-understood biology, available biomarkers, and significant unmet need for efficient clinical proof of concept.
Continues to invest in blood-brain barrier research, with a dedicated team and capital for strategic execution.
Clinical pipeline and program updates
On the verge of first approval for tividenofusp alfa (tivi/DNL310) in Hunter syndrome, with a PDUFA date set for April 5th after resolving a molecular weight miscalculation.
Two near-term launches: tividenofusp alfa (DNL310) in 2026 and DNL126 in 2027, targeting lysosomal storage disorders, with additional programs in FTD-GRN, Pompe, and Alzheimer's advancing.
Expanding clinical programs in rare diseases (Hunter, Sanfilippo, Pompe) and neurodegenerative diseases (Alzheimer's, FTD), with multiple readouts and filings expected through 2027.
SGSH for Sanfilippo selected for the FDA's START program, aiming for accelerated approval and leveraging learnings from the Hunter program to reduce timeline and cost.
DNL593 (PTV-Progranulin) for FTD has completed phase I-II enrollment, with biomarker data expected by year-end.
Technology differentiation and clinical data
TransportVehicle platform enables even brain distribution and enhanced delivery to other tissues, outperforming standard antibodies in preclinical models.
Demonstrated robust normalization of disease biomarkers and clinical improvements in cognition, behavior, and hearing in Hunter syndrome.
Safety profile shows declining infusion reactions and immune-silent engineering, with over 11,000 doses administered across programs.
Comparative studies show superior brain uptake and molecular stability versus other BBB technologies, with reduced ARIA risk in Alzheimer's models.
Platform modularity allows delivery of enzymes, antibodies, and oligonucleotides, with first oligonucleotide program entering the clinic.
ETV franchise launch strategy for rapid uptake
DNL921's competitive edge in AD market
Pipeline funding strategy beyond near-term launches
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Denali Therapeutics earnings date
Q4 202527 Feb, 2026
Denali Therapeutics
Next Denali Therapeutics earnings date
Q4 202527 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Denali Therapeutics Inc is a biotechnology company focused on developing therapies for neurodegenerative diseases. The company researches and creates treatments targeting conditions such as Alzheimer's disease, Parkinson’s disease, and other disorders affecting the central nervous system. Denali Therapeutics operates within the healthcare and biotechnology sectors. The company is headquartered in South San Francisco, California, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage